In contrast, treatment with CD38-specific hcAbs or with daratumumab resulted in significant inhibition of tumor cell growth as compared with isotype control treatment from day 28 (all p<0.001, as compared with isotype control treatment from day 28) (Figure 5B). This evidence concerns the gene CD38 and neoplasm.